Grandfield & Dodd LLC Purchases New Position in Exelixis, Inc. (NASDAQ:EXEL)

Grandfield & Dodd LLC acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,020 shares of the biotechnology company’s stock, valued at approximately $312,000.

A number of other institutional investors also recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new position in shares of Exelixis during the third quarter worth approximately $30,000. Park Place Capital Corp bought a new position in Exelixis during the 2nd quarter worth $45,000. GAMMA Investing LLC lifted its holdings in shares of Exelixis by 107.9% during the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,041 shares in the last quarter. EntryPoint Capital LLC boosted its position in shares of Exelixis by 537.2% in the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 1,746 shares during the period. Finally, Capital Performance Advisors LLP acquired a new position in shares of Exelixis in the third quarter valued at about $61,000. Institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In other news, EVP Jeffrey Hessekiel sold 20,000 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $25.79, for a total value of $515,800.00. Following the completion of the sale, the executive vice president now owns 630,325 shares of the company’s stock, valued at approximately $16,256,081.75. This represents a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Dana Aftab sold 1,162 shares of Exelixis stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total value of $36,486.80. Following the completion of the transaction, the executive vice president now directly owns 498,945 shares in the company, valued at approximately $15,666,873. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 289,736 shares of company stock worth $9,471,510. 2.85% of the stock is currently owned by company insiders.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $34.41 on Wednesday. Exelixis, Inc. has a 52-week low of $19.20 and a 52-week high of $36.60. The company has a market capitalization of $9.83 billion, a PE ratio of 22.06, a price-to-earnings-growth ratio of 0.88 and a beta of 0.51. The company has a fifty day moving average of $29.39 and a 200-day moving average of $25.35.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.04. The company had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 earnings per share. On average, equities analysts forecast that Exelixis, Inc. will post 1.68 EPS for the current fiscal year.

Analysts Set New Price Targets

EXEL has been the subject of a number of recent research reports. Stifel Nicolaus boosted their price objective on shares of Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday, October 16th. Bank of America boosted their price target on Exelixis from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. BMO Capital Markets raised their price objective on Exelixis from $29.00 to $36.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Stephens upped their target price on Exelixis from $23.00 to $29.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. Finally, HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Exelixis in a report on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.44.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.